Home  »  Companies   »  Agenus Inc. (AGEN) Volatility At 6.86%, Should You...

Agenus Inc. (AGEN) Volatility At 6.86%, Should You Add A Position?

192 institutions hold shares in Agenus Inc. (AGEN), with 16.62M shares held by insiders accounting for 8.12% while institutional investors hold 57.07% of the company’s shares. The shares outstanding are 192.97M, and float is at 173.55M with Short Float at 13.85%. Institutions hold 52.44% of the Float.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Blackrock Inc. with over 14.52 million shares valued at $46.17 million. The investor’s holdings represent 7.09% of the AGEN Shares outstanding. As of Dec 30, 2020, the second largest holder is RTW Investments LP with 12.86 million shares valued at $40.91 million to account for 6.29% of the shares outstanding. The other top investors are Oracle Investment Management Inc which holds 11.85 million shares representing 5.79% and valued at over $37.69 million, while State Street Corporation holds 5.03% of the shares totaling 10.3 million with a market value of $32.76 million.

Agenus Inc. (NASDAQ: AGEN) is -4.40% lower on its value in year-to-date trading and has touched a low of $2.27 and a high of $5.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AGEN stock was last observed hovering at around $2.87 in the last trading session, with the day’s gains setting it 0.17% off its average median price target of $7.50 for the next 12 months. It is also 62.0% off the consensus price target high of $8.00 offered by 3 analysts, but current levels are 56.57% higher than the price target low of $7.00 for the same period.

Currently trading at $3.04, the stock is -0.41% and -18.98% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.79 million and changing 5.92% at the moment leaves the stock -20.30% off its SMA200. AGEN registered 28.27% gain for a year compared to 6-month loss of -24.94%. The firm has a 50-day simple moving average (SMA 50) of $3.4576 and a 200-day simple moving average (SMA200) of $3.7620.

The stock witnessed a -3.80% gain in the last 1 month and extending the period to 3 months gives it a -4.40%, and is 6.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.86% over the week and 7.54% over the month.

Agenus Inc. (AGEN) has around 359 employees, a market worth around $589.67M and $88.20M in sales. Distance from 52-week low is 33.92% and -48.91% from its 52-week high.

Agenus Inc. (AGEN) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Agenus Inc. (AGEN) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.30, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Agenus Inc. is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.31 with sales reaching $14.54M over the same period.The EPS is expected to shrink by -31.40% this year, but quarterly earnings will post -13.30% year-over-year. Quarterly sales are estimated to shrink -3.90% in year-over-year returns.

Agenus Inc. (AGEN) Insider Activity

The most recent transaction is an insider sale by INCYTE CORP, the company’s 10% Owner. SEC filings show that INCYTE CORP sold 141,920 shares of the company’s common stock on Jun 17 at a price of $3.66 per share for a total of $0.52 million. Following the sale, the insider now owns 16.97 million shares.

Agenus Inc. disclosed in a document filed with the SEC on Jun 16 that INCYTE CORP (10% Owner) sold a total of 72,080 shares of the company’s common stock. The trade occurred on Jun 16 and was made at $3.66 per share for $0.26 million. Following the transaction, the insider now directly holds 17.11 million shares of the AGEN stock.

Still, SEC filings show that on Jun 15, INCYTE CORP (10% Owner) disposed off 384,025 shares at an average price of $3.57 for $1.37 million. The insider now directly holds 17,186,968 shares of Agenus Inc. (AGEN).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Agenus Inc. (AGEN): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 22.74% up over the past 12 months and Bristol-Myers Squibb Company (BMY) that is 14.40% higher over the same period. Short interest in the company’s stock has risen 0.96% from the last report on Feb 11, 2021 to stand at a total of 23.81 million short shares sold with a short interest ratio of 7.93.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts




Download Free eBook For

100% free. stop anytime no spam


Download free eBook for